Clonidine

Source: Wikipedia, the free encyclopedia.
(Redirected from
Clonidine hydrochloride
)

Clonidine
Clinical data
Pronunciation/ˈklɒnədn/
Trade namesCatapres, Kapvay, Nexiclon, others
AHFS/Drugs.comMonograph
MedlinePlusa682243
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Oral, epidural, intravenous (IV), transdermal, topical
Drug classCentrally acting α2A-agonist hypotensive agent
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability70–80% (oral),[2][3] 60–70% (transdermal)[4]
Protein binding20–40%[5]
MetabolismLiver to inactive metabolites,[5] 2/3 CYP2D6[9]
Onset of actionIR: 30–60 minutes after an oral dose[6]
Elimination half-lifeIR: 12–16 hours; 41 hours in kidney failure,[7][8] 48 hours for repeated dosing[4]
ExcretionUrine (72%)[5]
Identifiers
  • N-(2,6-Dichlorophenyl)-4,5--1H-imidazol-2-amine
JSmol)
  • Clc1cccc(Cl)c1N/C2=N/CCN2
  • InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14) checkY
  • Key:GJSURZIOUXUGAL-UHFFFAOYSA-N checkY
  (verify)

Clonidine, sold under the brand name Catapres among others, is an α2A-adrenergic agonist[10] medication used to treat high blood pressure, ADHD, drug withdrawal (alcohol, opioids, or nicotine), menopausal flushing, diarrhea, spasticity, and certain pain conditions.[11] The drug is often prescribed off-label for tics. It is used orally (by mouth), by injection, or as a transdermal skin patch.[11] Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours.[11]

Common side effects include dry mouth, dizziness, headaches, hypotension, and sleepiness.

heart arrhythmias, and confusion.[12] If rapidly stopped, withdrawal effects may occur.[11] Use during pregnancy or breastfeeding is not recommended.[12] Clonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries.[11]

Clonidine was patented in 1961 and came into medical use in 1966.

generic medication.[11] In 2021, it was the 80th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[16][17]

Medical uses

Clonidine tablets and transdermal patch

Clonidine is used to treat high blood pressure, attention deficit hyperactivity disorder (ADHD), drug withdrawal (alcohol, opioids, or smoking), menopausal flushing, diarrhea, and certain pain conditions. It also sees some use off-label for episodic insomnia, restless-legs syndrome, and anxiety, among other uses.[11]

Resistant hypertension

Clonidine may be effective for lowering blood pressure in people with resistant hypertension.[18]

Clonidine works by slowing the

catecholamines.[19]

Attention deficit hyperactivity disorder

Clonidine may improve symptoms of attention deficit hyperactivity disorder in some people but causes many adverse effects and the beneficial effect is modest.[20] In Australia, clonidine is an accepted but not approved use for ADHD by the TGA.[21] Clonidine, along with methylphenidate, has been studied for treatment of ADHD.[22][23][24] While not as effective as methylphenidate in treating ADHD, clonidine does offer some benefit;[22] it can also be useful in combination with stimulant medications.[25] Some studies show clonidine to be more sedating than guanfacine, which may be better at bedtime along with an arousing stimulant in the morning.[26][27] Clonidine has been used to reduce sleep disturbances in ADHD, including to help offset stimulant-associated insomnia.[28][29][30][31] Unlike stimulant medications, clonidine is regarded as having no abuse potential, and may even be used to reduce abuse of drugs including nicotine and cocaine.[32]

In the US, only the extended-release form of clonidine is approved for ADHD treatment.[33]

Drug withdrawal

Clonidine may be used to ease drug withdrawal symptoms associated with abruptly stopping the long-term use of

benzodiazepines and nicotine.[34] It can alleviate opioid withdrawal symptoms by reducing the sympathetic nervous system response such as tachycardia and hypertension, hyperhidrosis (excessive sweating), hot and cold flashes, and akathisia.[35] It may also be helpful in aiding smokers to quit.[36] The sedation effect can also be useful. Clonidine may also reduce severity of neonatal abstinence syndrome in infants born to mothers that are using certain drugs, particularly opioids.[37] In infants with neonatal withdrawal syndrome, clonidine may improve the neonatal intensive care unit Network Neurobehavioral Score.[38]

Clonidine has also been suggested as a treatment for rare instances of dexmedetomidine withdrawal.[39]

Spasticity

Clonidine has some role in the treatment of spasticity, acting principally by inhibiting excessive sensory transmission below the level of injury[

intrathecally,[41] which confers various benefits, including a reduction or prevention of the blood pressure lowering effects and increased effectiveness against spasticity.[42] The effectiveness of intrathecal clonidine is comparable to that of intrathecal baclofen for spasticity.[42]

Clonidine suppression test

The reduction in circulating norepinephrine by clonidine was used in the past as an investigatory test for

phaeochromocytoma, which is a catecholamine-synthesizing tumor, usually found in the adrenal medulla.[43] In a clonidine suppression test, plasma catecholamine levels are measured before and 3 hours after a 0.3 mg oral test dose has been given to the patient. A positive test occurs if there is no decrease in plasma levels.[43]

Other uses

Clonidine also has several

tics).[61] Clonidine has also had some success in clinical trials for helping to remove or ameliorate the symptoms of hallucinogen persisting perception disorder (HPPD).[62]

Injection of α2 receptor agonists into the knee joint space, including clonidine, may reduce the severity of knee pain after arthroscopic knee surgery.[63]

Light-activated derivatives of clonidine (adrenoswitches) have been developed for research purposes and shown to control pupillary reflex with light in blind mice by topical application.[64]

Pregnancy and breastfeeding

It is classified by the TGA of Australia as pregnancy category B3, which means that it has shown some detrimental effects on fetal development in animal studies, although the relevance of this to human beings is unknown.[65] Clonidine appears in high concentration in breast milk; a nursing infant's serum clonidine concentration is approximately 2/3 of the mother's.[66] Caution is warranted in women who are pregnant, planning to become pregnant, or are breastfeeding.[67]

Adverse effects

The principal adverse effects of clonidine are sedation, dry mouth, and hypotension (low blood pressure).[5]

By frequency[65][68]

Very common (>10% frequency):

Common (1–10% frequency):

  • Anxiety
  • Constipation
  • Sedation (dose-dependent)
  • Nausea/vomiting
  • Malaise
  • Abnormal LFTs
  • Rash
  • Weight gain/loss
  • Pain below the ear (from salivary gland)
  • Erectile dysfunction

Uncommon (0.1–1% frequency):

Rare (<0.1% frequency):

Withdrawal

Because clonidine suppresses sympathetic outflow, resulting in lower blood pressure, sudden discontinuation can result in acute hypertension due to a rebound in sympathetic outflow. In extreme cases, this can result in a hypertensive crisis, which is a medical emergency.[69]

Clonidine therapy should generally be gradually tapered when discontinuing therapy to avoid

rebound effects from occurring. Treatment of clonidine withdrawal hypertension depends on the severity of the condition. Reintroduction of clonidine for mild cases, alpha and beta blockers for more urgent situations. Beta blockers never should be used alone to treat clonidine withdrawal as alpha vasoconstriction would still continue.[70][71]

Pharmacology

Clonidine[72]
Site Ki (nM) Species Ref
NETTooltip Norepinephrine transporter >1,000 Human [73]
5-HT1B >10,000 Rat [74]
5-HT2A >10,000 Human [72]
α1A 316.23 Human [73]
α1B 316.23 Human [73]
α1D 125.89 Human [73]
α2A 35.48 – 61.65 Human [73][75]
α2B 69.18 – 309.0 Human [75][73]
α2C 134.89 – 501.2 Human [75][73]
D1
> 10,000 Rat [76]
I1 31.62 Bovine [73]
I2 (cortex) >1,000 Rat [73]
MAO-A >1,000 Rat [73]
MAO-B >1,000 Rat [73]
σ >10,000 Guinea Pig [77]
The Ki refers to a drug's affinity for a receptor. The smaller the Ki, the higher the affinity for that receptor.[78] Reported imidazoline-2 binding is measured in the cortex — I2 receptor bindings measured in stomach membranes are much lower.[79]

Mechanism of action

Clonidine crosses the blood–brain barrier.[7]

High blood pressure

Clonidine treats high blood pressure by stimulating

presynaptic α2 receptors in the vasomotor center in the brainstem. This binding has a sympatholytic effect, suppresses release of norepinephrine, ATP, renin, and neuropeptide Y which if released would increase vascular resistance.[10]
: 201–203 

Clonidine also acts as an agonist at imidazoline-1 (I1) receptors in the brain, and it is hypothesized that this effect may contribute to reducing blood pressure by reducing signaling in the sympathetic nervous system; this effect acts upstream of the central α2 agonist effect of clonidine.[10]: 201–203 [80]

Clonidine may also cause bradycardia, theoretically by increasing signaling through the vagus nerve. When given intravenously, clonidine can temporarily increase blood pressure by stimulating α1 receptors in smooth muscles in blood vessels.[81] This hypertensive effect is not usual when clonidine is given orally or by the transdermal route.[10]: 201–203 

Plasma concentration of clonidine exceeding 2.0 ng/mL does not provide further blood pressure reduction.[82]

Attention deficit hyperactivity disorder

Structural comparison between the neurotransmitter norepinephrine and the drug clonidine. Both drugs bind to α2 adrenergic receptors.[83] Similarities between the two structures are shown highlighted in red.

In the setting of attention deficit hyperactivity disorder (ADHD), clonidine's molecular mechanism of action occurs due to its agonism at the α2A adrenergic receptor, the subtype of the adrenergic receptor that is most principally found in the brain. Within the brain, the α2A adrenergic receptors are found within the prefrontal cortex (PFC), among other areas. The α2A adrenergic receptors are found on the presynaptic cleft of a given neuron, and, when activated by an agonist, the effect on downstream neurons is inhibitory. The inhibition is accomplished by preventing the secretion of the neurotransmitter norepinephrine. Thus, clonidine's agonism on α2A adrenergic receptors in the PFC inhibits the action of downstream neurons by preventing the secretion of norepinephrine.[83]

This mechanism is similar to the brain's physiological inhibition of PFC neurons by the

locus ceruleus (LC), which secretes norepinephrine into the PFC. Although norepinephrine can also bind to target adrenergic receptors on the downstream neuron (otherwise inducing a stimulatory effect), norepinephrine also binds to α2A adrenergic receptors (akin to clonidine's mechanism of action), inhibiting the release of norepinephrine by that neuron and inducing an inhibitory effect. Because the PFC is required for working memory and attention, it is thought that clonidine's inhibition of PFC neurons helps to eliminate irrelevant attention (and subsequent behaviors), improving the person's focus and correcting deficits in attention.[83]

Growth hormone test

Clonidine stimulates release of GHRH hormone from the hypothalamus, which in turn stimulates pituitary release of growth hormone.[84] This effect has been used as part of a "growth hormone test," which can assist with diagnosing growth hormone deficiency in children.[85]

Pharmacokinetics

After being ingested, clonidine is absorbed into the blood stream rapidly with an overall

kidneys.[86] About one-fifth of an oral dose will not be absorbed, and is thus excreted in the feces.[86] Work with liver microsomes shows in the liver clonidine is primarily metabolized by CYP2D6 (66%), CYP1A2 (10–20%), and CYP3A (0–20%) with negligible contributions from the less abundant enzymes CYP3A5, CYP1A1, and CYP3A4.[9] 4-hydroxyclonidine, the main metabolite of clonidine, is also an α2A agonist but is non lipophilic and is not believed to contribute to the effects of clonidine since it does not cross the blood–brain barrier.[89][90]

Measurements of the half-life of clonidine vary widely, between 6 and 23 hours, with the half-life being greatly affected by and prolonged in the setting of poor kidney function.[86] Variations in half-life may be partially attributable to CYP2D6 genetics.[9] Some research has suggested the half-life of clonidine is dose dependent and approximately doubles upon chronic dosing,[91] while other work contradicts this.[4] Following a 0.3 mg oral dose, a small study of five patients by Dollery et al. (1976) found half-lives ranging between 6.3 and 23.4 hours (mean 12.7).[92] A similar N=5 study by Davies et al. (1977) found a narrower range of half-lives, between 6.7 and 13 hours (average 8.6 hours),[2] while an N=8 study by Keraäen et al. that included younger patients found a somewhat shorter average half-life of 7.5 hours.[93]

History

Clonidine was introduced in 1966.[94] It was first used as a hypertension treatment under the trade name of Catapres.[95]

Society and culture

Brand names

As of June 2017, clonidine was marketed under many brand names worldwide: Arkamin, Aruclonin, Atensina, Catapin, Catapres, Catapresan, Catapressan, Chianda, Chlofazoline, Chlophazolin, Clonid-Ophtal, Clonidin, Clonidina, Clonidinã, Clonidine, Clonidine hydrochloride, Clonidinhydrochlorid, Clonidini, Clonidinum, Clonigen, Clonistada, Clonnirit, Clophelinum, Dixarit, Duraclon, Edolglau, Haemiton, Hypodine, Hypolax, Iporel, Isoglaucon, Jenloga, Kapvay, Klofelino, Kochaniin, Lonid, Melzin, Menograine, Normopresan, Paracefan, Pinsanidine, Run Rui, and Winpress.[96] It was marketed as a combination drug with chlortalidone as Arkamin-H, Bemplas, Catapres-DIU, and Clorpres, and in combination with bendroflumethiazide as Pertenso.[96]

References

  1. FDA
    . Retrieved 22 October 2023.
  2. ^
    S2CID 5566079
    .
  3. ^ "Catapres- clonidine hydrochloride tablet". DailyMed. 6 September 2016. Archived from the original on 4 August 2020. Retrieved 21 December 2019. The pharmacokinetics of clonidine is dose-proportional in the range of 100 to 600 µg.The absolute bioavailability of clonidine on oral administration is 70% to 80%. Peak plasma clonidine levels are attained in approximately 1 to 3 hours.
  4. ^
    S2CID 24783447
    .
  5. ^ a b c d "clonidine (Rx) - Catapres, Catapres-TTS, more." Medscape Reference. WebMD. Archived from the original on 4 December 2020. Retrieved 10 November 2013.
  6. ^ "Catapres- clonidine hydrochloride tablet". DailyMed. 6 September 2016. Archived from the original on 4 August 2020. Retrieved 21 December 2019. Catapres tablets act relatively rapidly. The patient's blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease occurring within 2 to 4 hours.
  7. ^ a b "Catapres- clonidine hydrochloride tablet". DailyMed. 6 September 2016. Archived from the original on 4 August 2020. Retrieved 21 December 2019. Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours. The half-life increases up to 41 hours in patients with severe impairment of renal function. Clonidine crosses the placental barrier. It has been shown to cross the blood–brain barrier in rats.
  8. ^ "Kapvay". RxList. Archived from the original on 12 October 2017. Retrieved 30 October 2014.
  9. ^
    PMID 20570945
    .
  10. ^ .
  11. ^ a b c d e f g h "Clonidine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 3 February 2019. Retrieved 2 February 2019.
  12. ^ .
  13. .
  14. .
  15. from the original on 29 April 2023. Retrieved 12 September 2020.
  16. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  17. ^ "Clonidine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  18. PMID 29863319
    .
  19. ^ "CATAPRES- clonidine hydrochloride tablet". DailyMed. 6 September 2016. Archived from the original on 4 August 2020. Retrieved 21 December 2019. Slowing of the pulse rate has been observed in most patients given clonidine, but the drug does not alter normal hemodynamic response to exercise. Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines.
  20. PMID 10596256
    .
  21. .
  22. ^ .
  23. .
  24. .
  25. .
  26. .
  27. from the original on 9 August 2014. Retrieved 1 August 2014.
  28. ^ .
  29. .
  30. .
  31. .
  32. .
  33. ^ "Highlights of Prescribing Information: Kapvay" (PDF). US FDA. Retrieved 31 March 2024.
  34. PMID 24151426
    .
  35. ^ Giannini AJ (1997). Drugs of Abuse (2nd ed.). Los Angeles: Practice Management Information.
  36. PMID 15266422
    .
  37. .
  38. .
  39. .
  40. .
  41. .
  42. ^ .
  43. ^ .
  44. .
  45. .
  46. .
  47. .
  48. .
  49. .
  50. .
  51. .
  52. .
  53. .
  54. .
  55. ^ "Treatment and Management of RLS". www.medscape.org. WebMD LLC. Archived from the original on 29 September 2017. Retrieved 3 October 2018.
  56. from the original on 26 July 2011. Retrieved 12 February 2012.
  57. .
  58. ^ "Clonidine Oral Uses". WebMD. Archived from the original on 25 October 2007. Retrieved 30 May 2007.
  59. ^ "Clonidine". Drugs.com. Archived from the original on 14 April 2017. Retrieved 25 May 2017.
  60. PMID 27134659
    .
  61. .
  62. .
  63. .
  64. .
  65. ^ a b "CATAPRES® 150 TABLETS CATAPRES® AMPOULES" (PDF). TGA eBusiness Services. Boehringer Ingelheim Pty Limited. 28 February 2013. Archived from the original on 16 January 2017. Retrieved 27 November 2013.
  66. from the original on 5 December 2020. Retrieved 5 January 2019.
  67. ^ "Clonidine". Prescription Marketed Drugs. www.drugsdb.eu. Archived from the original on 28 March 2012. Retrieved 2 August 2011.
  68. ^ "Clonidine 25 mcg Tablets BP - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Sandoz Limited. 2 August 2012. Archived from the original on 2 December 2013. Retrieved 27 November 2013.
  69. ^ Brayfield, A, ed. (13 January 2014). "Clonidine". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Archived from the original on 28 August 2021. Retrieved 28 June 2014.
  70. .
  71. .
  72. ^ a b Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 14 November 2022. Retrieved 14 August 2017.
  73. ^
    PMID 11082457
    .
  74. .
  75. ^ .
  76. .
  77. .
  78. .
  79. .
  80. .
  81. .
  82. ^ "CATAPRES- clonidine hydrochloride tablet". DailyMed. 6 September 2016. Archived from the original on 4 August 2020. Retrieved 21 December 2019. The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/mL in patients with normal excretory function. A further rise in the plasma levels will not enhance the antihypertensive effect.
  83. ^
    PMID 20652773
    .
  84. .
  85. ^ "Growth Hormone Test". www.cincinnatichildrens.org. Cincinnati Children's Hospital Medical Center. Archived from the original on 14 October 2018. Retrieved 13 October 2018.
  86. ^
    S2CID 28405271
    .
  87. .
  88. .
  89. .
  90. .
  91. .
  92. .
  93. .
  94. .
  95. ^ "Clonidine: Drug Uses, Dosage & Side Effects - Drugs.com". Drugs.com. Archived from the original on 14 April 2017. Retrieved 10 December 2017.
  96. ^ a b "Clonidine brand names". Drugs.com. Archived from the original on 6 August 2017. Retrieved 16 June 2017.

External links

  • Alpha-2 agonists in ADHD